These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 37009698)

  • 1. Targeting PD-1/PD-L1 in biliary tract cancer: role and available data.
    Mahmood RD; Graham K; Gleeson J; Hubner RA; Valle JW; McNamara MG
    Immunotherapy; 2023 May; 15(7):517-530. PubMed ID: 37009698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
    Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
    Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lacking Immunotherapy Biomarkers for Biliary Tract Cancer: A Comprehensive Systematic Literature Review and Meta-Analysis.
    Frega G; Cossio FP; Banales JM; Cardinale V; Macias RIR; Braconi C; Lamarca A
    Cells; 2023 Aug; 12(16):. PubMed ID: 37626908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer.
    Zhu C; Xue J; Wang Y; Wang S; Zhang N; Wang Y; Zhang L; Yang X; Long J; Yang X; Sang X; Zhao H
    Front Immunol; 2023; 14():1109292. PubMed ID: 36742297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer.
    Kim H; Kim J; Byeon S; Jang KT; Hong JY; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK; Kim ST
    Oncology; 2021; 99(6):365-372. PubMed ID: 33730723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China.
    Shi C; Li Y; Yang C; Qiao L; Tang L; Zheng Y; Chen X; Qian Y; Yang J; Wu D; Xie F
    Front Immunol; 2022; 13():946861. PubMed ID: 35967452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer.
    Rizzo A; Ricci AD; Brandi G
    Expert Opin Investig Drugs; 2021 Apr; 30(4):343-350. PubMed ID: 33645367
    [No Abstract]   [Full Text] [Related]  

  • 9. Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer.
    Ruggieri AN; Yarchoan M; Goyal S; Liu Y; Sharon E; Chen HX; Olson BM; Paulos CM; El-Rayes BF; Maithel SK; Azad NS; Lesinski GB
    Clin Cancer Res; 2022 Oct; 28(19):4336-4345. PubMed ID: 35833954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atezolizumab: an investigational agent for the treatment of biliary tract cancer.
    Hack SP; Zhu AX
    Expert Opin Investig Drugs; 2021 Oct; 30(10):1007-1015. PubMed ID: 34459336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The predictive value of PD-L1 expression in response to anti-PD-1/PD-L1 therapy for biliary tract cancer: a systematic review and meta-analysis.
    Yoon SB; Woo SM; Chun JW; Kim DU; Kim J; Park JK; So H; Chung MJ; Cho IR; Heo J
    Front Immunol; 2024; 15():1321813. PubMed ID: 38605964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current progress in systemic therapy for biliary tract cancers.
    Sutherland M; Ahmed O; Zaidi A; Ahmed S
    J Hepatobiliary Pancreat Sci; 2022 Oct; 29(10):1094-1107. PubMed ID: 33735541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective cohort study on the efficacy and safety for combination therapy of immunotherapy, targeted agent, and chemotherapy versus immunochemotherapy or chemotherapy alone in the first-line treatment of advanced biliary tract carcinoma.
    Zeng J; Ma J; Zeng Z; Yang L; Jiang Y; Mo N; Ma F; Liu C; Li R; Tang J; Qin S; Jiang H
    J Gastrointest Oncol; 2023 Apr; 14(2):758-767. PubMed ID: 37201053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival benefit and biomarker of PD-1 inhibitor combination therapy in first-line of advanced biliary tract cancer: A retrospective study.
    Guo J; Zhou Q; Zhou M; Dai H; Li L; Qiu Y; Mao L; Liu B; Shen J
    Cancer Med; 2023 Nov; 12(22):20699-20711. PubMed ID: 37930138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF).
    Arkenau HT; Martin-Liberal J; Calvo E; Penel N; Krebs MG; Herbst RS; Walgren RA; Widau RC; Mi G; Jin J; Ferry D; Chau I
    Oncologist; 2018 Dec; 23(12):1407-e136. PubMed ID: 29853658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial.
    Chen X; Wu X; Wu H; Gu Y; Shao Y; Shao Q; Zhu F; Li X; Qian X; Hu J; Zhao F; Mao W; Sun J; Wang J; Han G; Li C; Xia Y; Seesaha PK; Zhu D; Li H; Zhang J; Wang G; Wang X; Li X; Shu Y
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33172881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer.
    Sun D; Ma J; Wang J; Han C; Qian Y; Chen G; Li X; Zhang J; Cui P; Du W; Wu Z; Chen S; Zheng X; Yue Z; Song J; Gao C; Zhao X; Cai S; Hu Y
    Cancer Immunol Immunother; 2019 Sep; 68(9):1527-1535. PubMed ID: 31535160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review.
    Shen T; Zheng S; Geng L; Liu Z; Xu J; Lin B; Qian J; Zheng S
    Technol Cancer Res Treat; 2020; 19():1533033820979703. PubMed ID: 33308041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer.
    Ahn S; Lee JC; Shin DW; Kim J; Hwang JH
    Sci Rep; 2020 Jul; 10(1):12348. PubMed ID: 32704067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.